Termine
Performance
26.11.2021

08.12.21 KKR & Co. Inc.
Analysts' Conference
08.12.21 Rheinmetall AG
Analystenveranstaltung
08.12.21 home24 SE
Telefonkonferenz
08.12.21 HelloFresh SE
Analystenveranstaltung
08.12.21 RCM Beteiligungs AG
Telefonkonferenz
08.12.21 Ichor Holdings, Inc.
Analystenveranstaltung
08.12.21 ProCredit Holding AG & Co. KGaA
Außerordentliche Hauptversammlung
08.12.21 TUI AG
Veröffentlichung Konzern-/Jahresabschluss
08.12.21 Private Equity Holding AG
Net Asset Value per 30. November 2021
08.12.21 Evotec SE
Analystenveranstaltung
08.12.21 ecotel communication ag
Analystenveranstaltung
08.12.21 Sberbank
IR Events
08.12.21 Sberbank
IR Events
08.12.21 Gesco AG
Analystenveranstaltung
08.12.21 wallstreet:online AG
Analystenveranstaltung
08.12.21 EQS Group AG
Analystenveranstaltung
08.12.21 HomeToGo SE
UBS Global TMT Virtual Conference

November

KW M D M D F S S
44 1 2 3 4 5 6 7
45 8 9 10 11 12 13 14
46 15 16 17 18 19 20 21
47 22 23 24 25 26 27 28
48 29 30          

Dezember

KW M D M D F S S
48     1 2 3 4 5
49 6 7 8 9 10 11 12
50 13 14 15 16 17 18 19
51 20 21 22 23 24 25 26
52 27 28 29 30 31    

Januar 2022

KW M D M D F S S
52           1 2
1 3 4 5 6 7 8 9
2 10 11 12 13 14 15 16
3 17 18 19 20 21 22 23
4 24 25 26 27 28 29 30
5 31            

 

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

Aktuelle Research-Studie

3U HOLDING AG

Original-Research: 3U HOLDING AG (von GSC Research GmbH): Halten

26. November 2021